Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772804 | 0.91 | NCF1 (0.37) | NCF1SLC6A3GNAI3GNAO1GNAI1 | |
| SCHEMBL25645331 | 0.84 | GNAO1 (0.43) | GNAI3GNAO1GNAI1 | |
| SCHEMBL13772759 | 0.82 | NCF1 (0.39) | NCF1SLC6A3GNAI3GNAO1GNAI1 | |
| SCHEMBL21350187 | 0.82 | SHBG (0.34) | GNAI3GNAO1GNAI1 | |
| SCHEMBL17327895 | 0.81 | CACNA2D1 (0.35) | NCF1SLC6A3 | |
| SCHEMBL23717806 | 0.80 | GNAO1 (0.43) | GNAI3GNAO1GNAI1 | |
| SCHEMBL23717673 | 0.80 | GNAO1 (0.43) | GNAI3GNAO1GNAI1 | |
| SCHEMBL19321573 | 0.79 | GNAI3 (0.42) | NCF1SLC6A3GNAI3GNAO1GNAI1 | |
| SCHEMBL22803237 | 0.79 | — | — | |
| SCHEMBL25557516 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | SCHRÖDINGER, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562884-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | NCF1 3036/4885SLC6A3 524/4885GNAI3 656/4885 |
| US-20230348424-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | APC, RCC2, CDC37 | NCF1 849/4885SLC6A3 4615/4885GNAI3 206/4885 |
| US-20230293532-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | NCF1 543/4885SLC6A3 4599/4885GNAI3 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.